Cardiovascular outcomes of patients treated for non-Hodgkin lymphoma with first-line doxorubicin-based chemotherapy

References

• Laurent C, Baron M, Amara N, et al. Impact of expert pathologic review of lymphoma diagnosis: study of patients from the French lymphopath network. J Clin Oncol. 2017;35(18):2008–2017.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the groupe d’Etudes des lymphomes de l’Adulte. Blood. 2010;116(12):2040–2045.
   PubMed Web of Science ®Google Scholar
• Luminari S, Ferrari A, Manni M, et al. Long-Term results of the FOLL05 trial comparing R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage symptomatic follicular lymphoma. J Clin Oncol. 2018;36(7):689–696.
   PubMed Web of Science ®Google Scholar
• Luminari S, Manni M, Galimberti S, et al. Response-Adapted postinduction strategy in patients with advanced-stage follicular lymphoma: the FOLL12 study. J Clin Oncol. 2022;40(7):729–739.
   PubMed Web of Science ®Google Scholar
• Récher C, Coiffier B, Haioun C, et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet. 2011;378(9806):1858–1867.
   PubMed Web of Science ®Google Scholar
• Dadson K, Calvillo-Argüelles O, Thavendiranathan P, et al. Anthracycline-induced cardiomyopathy: cellular and molecular mechanisms. Clin Sci. 2020;134(13):1859–1885.
   Web of Science ®Google Scholar
• Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(36):2768–2801.
   PubMed Web of Science ®Google Scholar
• Late Cardiac Effects of Doxorubicin Therapy for Acute Lymphoblastic Leukemia in Childhood | NEJM.
   Google Scholar
• Lipshultz SE, Colan SD, Gelber RD, et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med. 1991;324:808–15.
   Google Scholar
• Asselin BL, Devidas M, Chen L, et al. Cardioprotection and safety of dexrazoxane in patients treated for newly diagnosed T-Cell acute lymphoblastic leukemia or advanced-stage lymphoblastic Non-Hodgkin lymphoma: a report of the children’s oncology group randomized trial pediatric oncology group 9404. J Clin Oncol. 2016;34(8):854–862.
   PubMed Web of Science ®Google Scholar
• Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the groupe d’Etude des lymphomes folliculaires. Groupe d’Etude des lymphomes de l’Adulte. J Clin Oncol. 1997;15(3):1110–1117.
   PubMed Web of Science ®Google Scholar
• Common Terminology Criteria for Adverse Events (CTCAE). 2017. p. 147.
   Google Scholar
• Volkova M, Russell R. Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr Cardiol Rev. 2011;7(4):214–220.
   PubMedGoogle Scholar
• Armenian SH, Mertens L, Slorach C, et al. Prevalence of anthracycline-related cardiac dysfunction in long-term survivors of adult-onset lymphoma. Cancer. 2018;124(4):850–857.
   PubMed Web of Science ®Google Scholar
• Baech J, Hansen SM, Lund PE, et al. Cumulative anthracycline exposure and risk of cardiotoxicity; a Danish Nationwide Cohort study of 2440 lymphoma patients treated with or without anthracyclines. Br J Haematol. 2018;183(5):717–726.
   PubMed Web of Science ®Google Scholar
• Filomena D, Versacci P, Cimino S, et al. Echocardiographic long-term follow-up of adult survivors of pediatric cancer treated with dexrazoxane-anthracyclines association. Int J Cardiol. 2020;299:271–275.
   PubMed Web of Science ®Google Scholar
• Linschoten M, Kamphuis JAM, van Rhenen A, et al. Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis. Lancet Haematol. 2020;7(4):e295–e308.
   PubMed Web of Science ®Google Scholar
• Ayyappan SR, Diamond A, Gupta V, et al. Cardiovascular toxicity after therapy for diffuse large B cell lymphoma occurs early and results in decreased overall survival. Blood. 2016;128(22):105–105.
   Web of Science ®Google Scholar
• Cardinale D, Colombo A, Bacchiani G, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131(22):1981–1988.
   PubMed Web of Science ®Google Scholar
• Lee SF, Luque-Fernandez MA, Chen YH, et al. Doxorubicin and subsequent risk of cardiovascular diseases among survivors of diffuse large B-cell lymphoma in Hong Kong. Blood Advances. 2020;4(20):5107–5117.
   PubMed Web of Science ®Google Scholar
• Lyon AR, Dent S, Stanway S, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the cardio-oncology study group of the heart failure association of the European Society of Cardiology in collaboration with the international cardio-oncology society. Eur J Heart Fail. 2020;22(11):1945–1960.
   PubMed Web of Science ®Google Scholar
• Frey MK, Bergler-Klein J. Echocardiographic evaluation of patients undergoing cancer therapy. Eur Heart J Cardiovasc Imaging. 2021;22(4):375–382.
   PubMed Web of Science ®Google Scholar
• Mihalcea D, Florescu M, Bruja R, et al. 3D echocardiography, arterial stiffness, and biomarkers in early diagnosis and prediction of CHOP-induced cardiotoxicity in non-Hodgkin’s lymphoma. Sci Rep. 2020;10(1):18473.
   PubMed Web of Science ®Google Scholar
• Dexrazoxane: contraindicated in children and adolescents. WHO Drug Information. 2011;24(3):242.
   Google Scholar
• Rabinovich A, Weiss D, Weissman M, et al. Dexrazoxane does not affect treatment outcome in non-Hodgkin’s lymphoma patients. Am J Hematol. 2012;87(8):830–832.
   PubMed Web of Science ®Google Scholar
• Swenson CE, Bolcsak LE, Batist G, et al. Pharmacokinetics of doxorubicin administered i.v. as myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer. Anticancer Drugs. 2003;14(3):239–246.
   PubMed Web of Science ®Google Scholar
• Olivieri J, Perna GP, Bocci C, et al. Modern management of anthracycline-induced cardiotoxicity in lymphoma patients: low occurrence of cardiotoxicity with comprehensive assessment and tailored substitution by nonpegylated liposomal doxorubicin. Oncologist. 2017;22(4):422–431.
   PubMed Web of Science ®Google Scholar
• Visco C, Pregnolato F, Ferrarini I, et al. Efficacy of R-COMP in comparison to R-CHOP in patients with DLBCL: a systematic review and single-arm meta-analysis. Crit Rev Oncol Hematol. 2021;163:103377.
   PubMed Web of Science ®Google Scholar
• Fridrik MA, Jaeger U, Petzer A, et al. Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma. Eur J Cancer. 2016;58:112–121.
   PubMed Web of Science ®Google Scholar
• Sancho J, Fernández‐Alvarez R, Gual‐Capllonch F, et al. R‐COMP versus R‐CHOP as first‐line therapy for diffuse large B‐cell lymphoma in patients ≥60 years: results of a randomized phase 2 study from the Spanish GELTAMO group. Cancer Med. 2021;10(4):1314–1326.
   PubMed Web of Science ®Google Scholar
• Curigliano G, Lenihan D, Fradley M, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020;31(2):171–190.
   PubMed Web of Science ®Google Scholar